MedTrace Logo

An Individualised Treatment vs. a Minimal Program in Women With Late-term Shoulder Impairments After Breast Cancer.

NCT05277909 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-11-08

No results posted yet for this study

Summary

In breast cancer patients late-term upper limb sequelae, such as shoulder pain and impaired shoulder function remain common after primary breast cancer surgery. The aim of this trial is to evaluate whether an expert assessment of shoulder impairments, followed by an individualised treatment plan, is superior to a minimal physiotherapeutic rehabilitation program in reducing shoulder symptoms, assessed 12 weeks after initiation of treatment, among women with late-term shoulder impairments after primary breast cancer surgery.

Conditions

Interventions

OTHER

The expert assessment of shoulder impairments and individualised treatment plan

The participant's diagnosis based on the history, symptoms and clinical findings will be used to guide the individualised treatment plan.

OTHER

A minimal physiotherapeutic rehabilitation program delivered in a pamphlet

This pamphlet contains a program with minimal exercise recommendations for the shoulder consisting of mobility, stretching, strength exercises and tissue treatment.

Sponsors & Collaborators

  • Region of Southern Denmark

    collaborator OTHER

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Kim Gordon Ingwersen, PT, PhD · Vejle Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-04
Primary Completion
2022-10-10
Completion
2022-10-10

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05277909 on ClinicalTrials.gov